{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:58:30Z","timestamp":1773979110983,"version":"3.50.1"},"reference-count":74,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T00:00:00Z","timestamp":1438041600000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Venlafaxine is one of the most frequently prescribed antidepressants worldwide, despite its toxicity risk in overdose. Furthermore, the molecule has been recently identified at the EU\u2010wide level as one of the novel psychoactive substances. This paper aims at investigating the potential of misuse, taking into account both the existing literature and the analysis of the misusers' experiences as described in venlafaxine misuse web reports.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A literature search was performed using PubMed, Embase, and Medline. Posts\/threads relating to venlafaxine misuse issues were identified through Google\u00ae and Yahoo\u00ae English\u2010language searches. Resulting websites' data were then qualitatively assessed, and information was collected on a range of issues, including dosage, drug intake modalities, untoward drug effects, and association with other recreational drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A few literature case reports focusing on venlafaxine as a misusing drug were here identified. The molecule was here typically ingested or snorted at dosages up to 10\u201315 times higher than those clinically advised, obtaining MDMA\/amphetamine\u2010like stimulant and psychedelic effects. Polydrug misuse was commonly reported. Venlafaxine appeared to be widely available online for sale.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Physicians should carefully evaluate patients for history of drug dependence and observe them for signs of venlafaxine misuse. Copyright \u00a9 2015 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2476","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T07:15:45Z","timestamp":1438067745000},"page":"255-261","source":"Crossref","is-referenced-by-count":14,"title":["Venlafaxine as the \u2018baby ecstasy\u2019? Literature overview and analysis of web\u2010based misusers\u2032 experiences"],"prefix":"10.1002","volume":"30","author":[{"given":"Giulia","family":"Francesconi","sequence":"first","affiliation":[{"name":"Academic Department of Experimental and Clinical Medicine Polytechnic University of Marche  Ancona Italy"},{"name":"School of Life and Medical Sciences University of Hertfordshire  Hatfield Herts UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6882-3770","authenticated-orcid":false,"given":"Laura","family":"Orsolini","sequence":"additional","affiliation":[{"name":"Academic Department of Experimental and Clinical Medicine Polytechnic University of Marche  Ancona Italy"},{"name":"School of Life and Medical Sciences University of Hertfordshire  Hatfield Herts UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duccio","family":"Papanti","sequence":"additional","affiliation":[{"name":"Medical School of Trieste  Italy"},{"name":"School of Life and Medical Sciences University of Hertfordshire  Hatfield Herts UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Corkery","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences University of Hertfordshire  Hatfield Herts UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences University of Hertfordshire  Hatfield Herts UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2009.01462.x"},{"issue":"6","key":"e_1_2_7_3_1","first-page":"290","article-title":"Misuse of substances theoretically without abuse potential\u2014case series","volume":"66","author":"Anand JS","year":"2009","journal-title":"Przegl Lek"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088441"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03060.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.11.1999.suppl1.4"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90194-8"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041867"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7376.1332"},{"issue":"3","key":"e_1_2_7_10_1","first-page":"22","article-title":"Venlafaxine and serious withdrawal symptoms: warning to drivers","volume":"7","author":"Campagne DM","year":"2005","journal-title":"MedGenMed"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318272864d"},{"issue":"1","key":"e_1_2_7_12_1","first-page":"10","article-title":"CDC grand rounds: prescription drug overdoses: a U.S. epidemic","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR"},{"key":"e_1_2_7_13_1","unstructured":"Center for Drug Evaluation and Research.2000.APPLICATION NUMBER: NDA 20\u2010699\/8\u2010013. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/020699_s013_EFFEXOR_XR.pdf(accessed on Sept. 20 2014). Wyeth Pharmaceuticals Inc.: Philadelphia PA."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-010-0013-x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.1.41"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39098.457720.BE"},{"issue":"3","key":"e_1_2_7_17_1","first-page":"339","article-title":"Effect of venlafaxine and nicotine on the level of neurotransmitters and their metabolites in rat brains","volume":"61","author":"Czubak A","year":"2010","journal-title":"J Physiol Pharmacol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2012.07.011"},{"issue":"4","key":"e_1_2_7_19_1","first-page":"376","article-title":"Venlafaxine addiction without a history of alcohol and substance abuse: a case report","volume":"25","author":"E\u015fsizo\u011flu A","year":"2012","journal-title":"D\u00fc\u015f\u00fcnen Adam"},{"key":"e_1_2_7_20_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction.2014.EMCDDA\u2013Europol 2013 annual report on the implementation of council decision 2005\/387\/JHA. Implementation Reports Publications Office of the European Union: Luxembourg."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000147840.06947.46"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S37917"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.12.1760"},{"issue":"5","key":"e_1_2_7_24_1","first-page":"184","article-title":"Venlafaxine in adults with attention\u2010deficit\/hyperactivity disorder: an open clinical trial","volume":"57","author":"Findling RL","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A161"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-006-0039-6"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(01)01530-7"},{"key":"e_1_2_7_28_1","first-page":"92","article-title":"Venlafaxine extended release for the treatment of chronic pain","volume":"32","author":"Galvez R","year":"2004","journal-title":"Actas Esp Psiquiatr"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.23.3082"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.10.1642"},{"issue":"1","key":"e_1_2_7_31_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/1520-6394(2000)12:1+<77::AID-DA10>3.0.CO;2-1","article-title":"Efficacy of venlafaxine in mixed depression\u2010anxiety states","volume":"12","author":"Gorman Jack M","year":"2000","journal-title":"Depress Anxiety"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1121189X00006254"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.5.503"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.109.070219"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.154"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D344"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0708"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.39.1.50"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-010-0461-5"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb10136.x"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050151"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.703179"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31825d6c25"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1081\/ADA-100100588"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-4-63"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(86)90769-0"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2013.849974"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05029.x"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02266.x"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050638"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2396(20010301)39:3<257::AID-SYN1007>3.0.CO;2-1"},{"issue":"11","key":"e_1_2_7_52_1","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1523\/JNEUROSCI.21-11-04090.2001","article-title":"Dopamine attenuates prefrontal cortical suppression of sensory inputs to the basolateral amygdala of rats","volume":"21","author":"Rosenkranz JA","year":"2001","journal-title":"J Neurosci"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.05.010"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39041.445104.BE"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199606002-00011"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200302203480822"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D112"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1730-5"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0164-4"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1159\/000279302"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1159\/000321079"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20174"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31802e0017"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0105"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.4306\/pi.2011.8.1.74"},{"key":"e_1_2_7_66_1","volume-title":"Essential Psychopharmacology: The Prescriber's Guide","author":"Stahl SM","year":"2005"},{"key":"e_1_2_7_67_1","volume-title":"Essential psychopharmacology. Neuroscientific basis and practical applications","author":"Stahl SM","year":"2013"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.178.3.234"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6394(2000)12:1 <55::AID-DA7>3.0.CO;2-X"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.4415\/ANN_13_04_14"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110401800311"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115080-00007"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg062"},{"key":"e_1_2_7_74_1","volume-title":"Effexor (venlafaxine hydrochloride) tablets prescribing information","author":"Laboratories Wyeth","year":"2006"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01300.x"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2476","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T07:49:34Z","timestamp":1696405774000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1002\/hup.2476"],"URL":"https:\/\/doi.org\/10.1002\/hup.2476","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}